Mainz Biomed launches ColoAlert with Bioclinica in Romania

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, has launched its flagship product, ColoAlert — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) – with its partner Bioclinica, a leader in the Romanian healthcare sector.

The collaboration with Bioclinica adds significant value to Mainz Biomed’s mission, the company said in a press release Wednesday. Leveraging the renowned expertise and extensive network of Bioclinica, ColoAlert will immediately become available to a large portion of the Romanian population, Mainz Biomed has said.

Bioclinica, a supplier of healthcare products with over 25 years of experience in medical diagnostics, operates 15 associated laboratories and 146 collection points across Romania. Mainz Biomed and Bioclinica will collaborate on co-marketing activities to ensure the successful commercial launch of ColoAlert across the country, the company said in the press release.

Darin Leigh, Chief Commercial Officer of Mainz Biomed said: “Our collaboration demonstrates a shared commitment to introducing state-of-the-art diagnostic solutions that can have a transformative impact on public health. Early detection is paramount in combating diseases like colorectal cancer, and our collaboration with Bioclinica exemplifies our mission to ensure more people globally have access to diagnostic tests that can give them a life-changing headstart on this disease.”